8-K current report · filed Oct 23, 2026

Tango Therapeutics, Inc. (TNGX) 8-K Current Report: October 23, 2026

Item 7.01Item 8.01Item EX-99.1Item EX-99.2TNGX overview

Short answer

Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Updated Phase 1/2 trial results for vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors.

Tango Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Updated Phase 1/2 trial results for vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors
  • Results cover an ongoing clinical program, making emerging efficacy and safety data material to TNGX valuation
  • Detailed findings available in Exhibit 99.1 press release and Exhibit 99.2 presentation

Item 8.01 · Other Events

  • Daraxonrasib combination showed 82% ORR and 88% 9-month PFS in 22 efficacy-evaluable second- or third-line PDAC patients
  • Dose level 1 safety generally manageable, but 40% Grade 3 TRAEs and dose level 2 produced 3 DLTs in 2 patients
  • Zoldonrasib combination delivered 54% ORR, 61% 9-month PFS, and 97% DCR across 35 efficacy-evaluable patients
  • FDA discussions support a planned randomized registrational trial versus standard chemotherapy in first-line MTAP-deleted PDAC, targeted for first half 2027
  • Strategic reprioritization shifts resources to PRMT5 programs, halting selected research and reducing workforce approximately 14%

Item EX-99.1 · Exhibit EX-99.1

  • Phase 1/2 PDAC data: 82% ORR, 88% 9-month PFS, and 100% disease control in 22 efficacy-evaluable patients
  • Planned global Phase 3 in front-line MTAP-deleted PDAC targets 1H 2027, with ORR and PFS primary endpoints
  • Proposed regimen: vopimetostat 200 mg daily plus daraxonrasib 100 mg daily versus standard chemotherapy
  • Dose level 1 showed 40% Grade 3 TRAEs and 20% dose reductions, while dose level 2 produced 3 DLTs in 2 patients
  • Zoldonrasib combination delivered 54% ORR and 61% 9-month PFS across 35 efficacy-evaluable patients

Item EX-99.2 · Exhibit EX-99.2

  • PDAC update highlights 82% ORR and 88% 9-month PFS for vopimetostat plus daraxonrasib in MTAP-deleted disease
  • Phase 3 first-line trial planned for 1H 2027, targeting 484 patients with dual ORR and PFS primary endpoints
  • Dose level 1 showed no Grade 3 rash or stomatitis, no Grade 4 or 5 treatment-related adverse events
  • $1.0B cash and investments as of June 30, 2026, expected to fund PDAC late-stage development and ongoing programs
  • Expansion strategy targets MTAP-wild-type PDAC, NSCLC, and other cancers through RAS-inhibitor combinations

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tango Therapeutics, Inc. 8-K filings

Get the next TNGX 8-K as it lands

Follow TNGX for push alerts, or ask the research agent what this filing means.